l e t t e r s
Megalencephaly-capillary malformation (MCAP) and megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndromes are sporadic overgrowth disorders associated with markedly enlarged brain size and other recognizable features [1] [2] [3] [4] [5] . We performed exome sequencing in 3 families with MCAP or MPPH, and our initial observations were confirmed in exomes from 7 individuals with MCAP and 174 control individuals, as well as in 40 additional subjects with megalencephaly, using a combination of Sanger sequencing, restriction enzyme assays and targeted deep sequencing. We identified de novo germline or postzygotic mutations in three core components of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. These include 2 mutations in AKT3, 1 recurrent mutation in PIK3R2 in 11 unrelated families with MPPH and 15 mostly postzygotic mutations in PIK3CA in 23 individuals with MCAP and 1 with MPPH. Our data highlight the central role of PI3K-AKT signaling in vascular, limb and brain development and emphasize the power of massively parallel sequencing in a challenging context of phenotypic and genetic heterogeneity combined with postzygotic mosaicism.
As described in our recent clinical analysis in 42 children with MCAP or MPPH 4 , the former consists of megalencephaly (or sometimes hemimegalencephaly), associated growth dysregulation with variable asymmetry, developmental vascular anomalies, distal limb malformations (syndactyly and polydactyly), variable cortical malformation and a mild connective tissue dysplasia ( Fig. 1 and Supplementary Figs. 1 and 2). The patchy skin vascular malformations and asymmetric overgrowth seen in MCAP meet the criteria for the Klippel-Trenaunay subtype of vascular malformations and deregulated growth, which suggests that postzygotic mosaicism may be present in a subset of cases 6, 7 . The phenotype of MPPH resembles that of MCAP but lacks vascular malformations and syndactyly 4, 8 . We hypothesized that MCAP and MPPH result from mutations in the same pathway, and we therefore studied them together. Given the absence of recurrence of both syndromes in all reported families, we conducted exome sequencing in two parent-proband trios-one with MCAP (subject LR09-006; Fig. 1 ) and one with clinical features overlapping both MCAP and MPPH (subject LR08-018; Fig. 1 )-and searched for de novo mutations. We also performed exome sequencing in the oldest of three affected siblings with MPPH (subject LR00-016a1; Fig. 1 ) in the first known instance of familial recurrence of this syndrome, assuming either autosomal recessive inheritance or germline mosaicism in one parent.
We identified 247-254 rare protein-altering variants per proband that were not found in public variant databases or 112 other exomes (Online Methods and Supplementary Table 1) . Analysis of the trio with proband LR08-018 identified a de novo mutation in AKT3 (c.1393C>T; p.Arg465Trp; Supplementary Table 2) . Sanger sequencing of AKT3 in another 40 individuals with megalencephaly identified a second de novo mutation in this gene in subject LR11-354 (c.686A>G; p.Asn229Ser; Table 1 ), which supports mutations in AKT3 as a rare cause of megalencephaly (P = 0.002, calculated as the likelihood of observing a second de novo mutation in AKT3; Online Methods). AKT3 encodes the brain-predominant isoform of the AKT serine/threonine kinase, which is a major downstream mediator of PI3K signaling 9, 10 , leading us to focus on genes in this pathway in other individuals with megalencephaly.
Analysis of LR00-016a1 revealed four genes with one homozygous or two compound heterozygous mutations, consistent with autosomal recessive inheritance. However, filtering of variants using genomewide SNP data from all three affected siblings excluded all four chromosomal loci (Online Methods and Supplementary Table 3) . We next manually examined the list of 247 rare variants and identified a heterozygous mutation in PIK3R2 (c.1117G>A; p.Gly373Arg; Table 1 ), which encodes the p85β regulatory subunit of class IA PI3K 11 . Sanger sequencing confirmed the presence of the mutation in all three affected siblings and its absence in saliva and blood in both parents and the unaffected sister, showing germline mosaicism in one parent. Sequencing of PIK3R2 in 40 individuals with megalencephaly identified the same nucleotide change in 10 additional subjects with MPPH, and this mutation was shown to be de novo in all 7 subjects for whom parental DNA was available ( Table 1) . The mutation occurred at a CpG dinucleotide, which might explain its recurrence 12 .
We identified four candidate de novo variants in the trio with proband LR09-006 and confirmed a de novo substitution in the exon 3 splice-donor consensus sequence of BDP1 (Supplementary Table 2 ). Screening of BPD1 in 12 additional subjects detected no other de novo mutations, thus failing to support a causative role for this sequence change. Given the clinical presentation of MCAP and the recent report of postzygotic mutations of AKT1 in Proteus syndrome 13 , we speculated that MCAP might result from low-level mosaic mutations missed by our standard pipeline. In parallel, we performed a second analysis of de novo mutations in this trio by including the raw variants that did not meet our initial hard-filtering criteria (Online Methods). The second approach identified a missense change in PIK3CA (c.2740G>A; p.Gly914Arg; Supplementary Table 2), which encodes the p110α catalytic subunit of class IA PI3K 14 . This mutation was supported by 20 of 177 reads (11%) in the exome sequencing data, and it was confirmed to be de novo and mosaic by Sanger sequencing and a custom restriction enzyme assay (Online Methods and Supplementary  Fig. 3a) . We then sequenced the coding exons of PIK3CA in 29 individuals with megalencephaly with no mutations in AKT3 or PIK3R2 and identified 14 additional PIK3CA mutations, with mutant allele frequencies ranging from 10-50% (Table 1 and Supplementary Table 4) .
Standard variant calling in exomes from seven additional subjects with MCAP identified a mutation of PIK3CA (c.1133G>A; p.Cys378Tyr) that was supported by 68 of 250 reads (27%) in subject 44735 ( Table 1 and Online Methods). This mutation showed variable levels of mosaicism depending on the tissue tested (Supplementary Fig. 3b ). Manual inspection of the Sequence Alignment/Map (SAM) files of the remaining six subjects with MCAP of unknown cause using the Integrative Genomics Viewer (IGV) 15 revealed other candidate mosaic mutations in PIK3CA, with mutations represented by 2-15% of the total reads. To differentiate between sequencing errors and putative mutations, we systematically searched for low-level mosaicism of PIK3CA in the exomes from these 6 individuals and 174 control subjects (Online Methods and Supplementary Table 5 ). Although data from both cohorts contained many sites with 1 or 2 variant reads (most expected to be sequencing errors), we found only 12 variant sites supported by 3 or more reads. A significantly higher frequency of such sites was found in the MCAP cohort. Using a threshold of four variant reads, we identified candidate mosaic mutations in five of six affected individuals and none in control individuals (Supplementary Table 6 ). Sanger sequencing, a custom restriction enzyme assay or both confirmed all five mutations (Supplementary Table 4 ). The only remaining subject with MCAP of unknown cause (115422) had a mutation encoding a p.Ala1035Val variation that was supported by 3 of 185 reads (Supplementary Table 6 ), which was confirmed by Sanger sequencing and restriction enzyme assay in DNA from saliva and buccal swab. We previously found and validated the same nucleotide substitution in four tissues from another subject with MCAP (LR11-270; Supplementary Fig. 3c ). Six other variant sites supported by three reads were identified in five individuals, including two sites in subject 162-001P with MCAP in addition to the pathogenic mutation, neither of which was confirmed by Sanger sequencing in blood or saliva, and four sites in control individuals. This suggests that variant sites supported by one to three reads are mostly sequencing artifacts (Supplementary Table 6 ).
Given the limitations of Sanger sequencing for detecting low-level mosaic mutations, we performed targeted ultra-deep sequencing (coverage of >10,000 reads) of 5 mutation sites in 15 mutation-negative affected individuals, as well as in known mutation carriers and control individuals (Online Methods and Supplementary Table 7 ). This experiment confirmed all previously identified mutations and detected two additional low-level mosaic mutations missed by Sanger sequencing ( Table 2 ). Both were confirmed by a second deep-sequencing experiment and showed mutant allele frequencies ranging from 1-8%.
Class IA PI3Ks are heterodimeric enzymes that convert phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to phosphatidylinositol 4,5-trisphosphate (PIP 3 ), a reaction that is reversed by the PTEN phosphatase 16 . This reaction leads to activation of the PI3K-AKT-mTOR network, which can be monitored by examining the extent of Figure 1 Craniofacial appearance and magnetic resonance imaging (MRI) of the three index subjects. (a-c) Photographs and brain MRI of subjects LR08-018 (a), LR00-016a1 (b) and LR09-006 (c). Left, photos of subjects LR08-018, LR00-016a1 and LR09-006 were taken at 11 months, 15 years and 5 months, respectively. Note the prominent forehead and apparent macrocephaly in all three and a midline facial capillary malformation (or nevus flammeus) in LR09-006. Center, midline sagittal brain images show prominent forehead, increased cranium-to-face ratio and cerebellar tonsillar ectopia (arrowheads), whereas axial or coronal images (right) show bilateral perisylvian polymicrogyria (arrows). Scale bars, 1 cm. Additional photographs of LR09-006 and a clinical description of the three index subjects are provided in the supplementary Note. We obtained written consent to publish photographs of these individuals.
npg l e t t e r s phosphorylation of downstream targets, such as S6 ribosomal protein and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) 17 . To assess the impact of AKT3, PIK3R2 and PIK3CA mutations on PI3K activity, we used immunostaining to compare PIP 3 amounts in lymphoblastoid cell lines derived from four mutation carriers with megalencephaly to those in control and PTEN-mutant cells (Fig. 2) . Consistent with elevated PI3K activity-and similar to what is seen with PTEN loss-all three lines with PIK3R2 or PIK3CA mutations showed significantly more PIP 3 staining than control cells (Fig. 2b) , as well as greater localization of active phosphoinositidedependent kinase 1 (PDK1) to the cell membrane 18 ( Supplementary  Fig. 4) . Treatment with the PI3K inhibitor PI-103 resulted in less PIP 3 in the PIK3R2 p.Gly373Arg and PIK3CA p.Glu453del mutant lines, confirming that these observations are PI3K-dependent (Fig. 2c) . We found no evidence for increased PI3K activity in the AKT3-mutant line, consistent with a mutation affecting a downstream effector of PI3K. Protein blot analysis showed higher amounts of phosphorylated S6 protein and 4E-BP1 in all mutant cell lines compared to controls (Supplementary Fig. 5 ). Although PI-103 treatment reduced S6 phosphorylation in control and mutant lines, the latter showed relative resistance to PI3K inhibition, consistent with elevated signaling through the pathway. Taken together, these observations support the conclusion that the megalencephaly-associated mutations result in higher PI3K activity and PI3K-mTOR signaling.
The PI3Ks are a highly conserved family of signaling enzymes that regulate a wide range of processes, including cell growth, proliferation, survival, migration, metabolism, angiogenesis, apoptosis, tumorigenesis and brain development 16, 17, [19] [20] [21] . As the predominant downstream effector of PI3K signaling, AKT kinases are involved in a wide range of human diseases and have a critical role in growth regulation 10 . Extensive mouse and human data have shown that loss-and gain-of-function mutations in the genes encoding the AKT isoforms lead to opposite phenotypes 13, [22] [23] [24] [25] . Several reports have shown that heterozygous loss of AKT3 in humans and homozygous loss in mice cause microcephaly [26] [27] [28] , whereas a heterozygous missense mutation in Akt3 (encoding p.Asp219Val) resulting in increased kinase activity was shown to cause seizures and brain overgrowth in mice 29 . This phenotype resembles the clinical presentation of the two AKT3 npg l e t t e r s mutation carriers in our study (Supplementary Table 8 ). Further, another group recently reported that somatic activating mutations in AKT3 in brain cause hemimegalencephaly 30 . Many subjects in our series had asymmetric brain enlargement, and several were diagnosed with hemimegalencephaly ( Supplementary Fig. 2 ). These data, combined with our observations of higher S6 and 4E-BP1 phosphorylation in a lymphoblastoid cell line harboring the AKT3 p.Arg465Trp alteration, strongly suggest a gain-of-function mechanism resulting in enhanced AKT activity for the two AKT3 mutations reported here. Class IA PI3K dimers are composed of a p110 catalytic subunit and a p85 regulatory subunit, each of which has three isoforms encoded by three genes 17 . Mutations in five of these genes (PIK3CA, PIK3CB, PIK3CD, PIK3R1 and PIK3R2) have been observed in many human cancers [31] [32] [33] [34] . Our data show that mutations affecting the p85β (PIK3R2) regulatory and p110α (PIK3CA) catalytic subunits are a common cause of megalencephaly syndromes, albeit with a clear genotype-phenotype correlation, as PIK3R2 and PIK3CA mutations are associated with MPPH (P = 3.3 × 10 −6 ) and MCAP (P = 1.0 × 10 −6 ), respectively (Online Methods and Supplementary Table 9 ). Both PIK3R1 and PIK3R2 have oncogenic potential, and alterations-including the glycine-to-arginine substitution in PIK3R2 found in MPPH (p.Gly373Arg) and substitution of the homologous amino-acid residue in PIK3R1 (p.Gly376Arg)-have been found in cancer 32 . Available functional studies showed that several of these alterations disrupt the inactive conformation of the PI3K dimer and maintain the catalytic subunit in a npg l e t t e r s high-activity state 32, 35 . Our observations in lymphoblastoid cells derived from subject LR00-016a1 show that the p.Gly373Arg alteration results in increased PI3K activity and elevated PI3K-mTOR signaling, further supporting this mechanism. We identified 24 affected individuals with PIK3CA mutations, and all but three (LR06-220, LR11-153 and LR11-230) showed evidence of postzygotic mosaicism. These mutations were discovered and confirmed by independent experiments using four different methods and multiple, mostly uncultured tissues, thus ruling out the possibility of cell culture or technology artifacts. As in the study on Proteus syndrome 13 , we observed lower levels of mosaicism in blood compared to other tissues (Supplementary Table 4) .
Somatic activating mutations in PIK3CA are frequently observed in several common human tumor types 20 . This may partly explain the mildly higher (~3%) incidence of cancer in individuals with MCAP and MPPH (Supplementary Table 10 and Supplementary Note). Three mutation hotspots (encoding p.Glu542Lys, p.Glu545Lys and His1047Arg) account for 80% of all tumor-associated PIK3CA mutations and show the highest oncogenic activity 20, 33 . Although 13 of 15 PIK3CA mutations found in our megalencephaly cohort are reported in the Catalogue of Somatic Mutations in Cancer (COSMIC ; Table 1) , only 1 subject with megalencephaly carried 1 of these severe PIK3CA cancer mutation hotspots (LR12-033; Table 1 ). Notably, the brain phenotype of this individual appeared more severe than that of other affected subjects (Supplementary Fig. 2 ). Among the MCAP-causing mutations previously associated with cancer, functional data reported for the mutations encoding p.Arg88Gln, p.Glu365Lys, p.Glu545Lys, p.Met1043Ile and p.His1047Tyr show increased lipid kinase activity resulting in constitutive PI3K signaling [36] [37] [38] , consistent with our observations of increased PI3K activity and signaling in lymphoblastoid cell lines from subjects with MCAP carrying PIK3CA mutations.
Altogether, we identified germline or postzygotic mutations of AKT3, PIK3R2 or PIK3CA in 37 of 50 (74%) unrelated probands ( Fig. 3 and Supplementary Table 9 ). Mutations of all three genes led to pre-and postnatal overgrowth of brain and variably body. The brain overgrowth phenotype universally included significant megalencephaly and reduced extra-axial spaces and was frequently accompanied by polymicrogyria, hydrocephalus and cerebellar tonsillar ectopia, including Chiari malformation (Supplementary Table 8) . Individuals with MCAP also presented striking-often asymmetricovergrowth of many other tissues, especially vascular, subcutaneous, connective and lymphatic tissues. Considering the clinical complexity of these syndromes and the potential importance of our findings for clinical care, we have summarized our provisional recommendations for clinical management in the Supplementary Note.
Although we cannot rule out the possibility of low-level mosaic mutations that are undetectable by Sanger sequencing, none of the 13 individuals with MCAP of unknown cause had mutations in PTEN or the four other genes encoding subunits of class IA PI3K (Online Methods). Further, some of these subjects might carry mosaic PIK3CA mutations undetectable by Sanger sequencing in the tissues tested. Our data emphasize the challenges of detecting low-level mosaic mutations but, nonetheless, highlight the power of massively parallel sequencing for discovering postzygotic mutations across the genome.
MPPH and MCAP share clinical features with Proteus syndrome and a spectrum of overgrowth disorders resulting from loss-of-function mutations in PTEN, including Bannayan-Riley-Ruvalcaba syndrome, Cowden disease and autism with severe megalencephaly [39] [40] [41] . Our results extend the list of overgrowth syndromes associated with aberrant PI3K-AKT signaling and show that dysfunction in this pathway causes a constellation of brain, vascular and limb malformations. Finally, our findings, in combination with the development of PI3K inhibitors for the treatment of human disease 42, 43 , may open the door to new therapeutic opportunities for megalencephaly and other developmental disorders. 
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